Results 11 to 20 of about 21,080,479 (286)
International Journal of Molecular Sciences, 2020 CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
Aamir Ahmad
openaire +3 more sources
Cancer Stem Cell as Target of CAR-T Cell Therapy [PDF]
E3S Web of Conferences, 2020 Chimeric antigen receptor-T cell (CAR-T) therapy has been studied intensively these years and is considered a promising cancer treatment. So far, Food and Drug Administration has approved 2 CAR-T cell therapy for patients with refractory leukemia and the
Li Xinran
doaj +2 more sources
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy. [PDF]
, 2022 Chimeric antigen receptor T-cells (CAR T) treatment has become a standard option for patients with diffuse large B-cell lymphomas (DLBCL), which are refractory or relapse after two prior lines of therapy.
Rentsch, Vera +13 more
core +2 more sources
, 2023 Breast cancer represents one of the most common tumor histologies. To date, based on the specific histotype, different therapeutic strategies, including immunotherapies, capable of prolonging survival are used. More recently, the astonishing results that
Caterina Gianni +8 more
core +2 more sources
Hematology/Oncology and Stem Cell Therapy, 2022 Chimeric antigen receptor T-cell (CAR T-cell) therapy represents an innovative and transformative therapy for patients with relapsed and/or refractory (R/R) hematological malignancies.
Farah Yassine +4 more
doaj +1 more source
Frontiers in Oncology, 2021 CAR T-cell therapy has revolutionized the treatment approach to patients with relapsed/refractory hematologic malignancies; however, there continues to be opportunity for improvement in treatment toxicity as well as response durability. Radiation therapy
Penny Q. Fang +7 more
doaj +1 more source
CAR-T Cell Therapy for Lymphoma [PDF]
Annual Review of Medicine, 2016 Lymphomas arise from clonal expansions of B, T, or NK cells at different stages of differentiation. Because they occur in the immunocyte-rich lymphoid tissues, they are easily accessible to antibodies and cell-based immunotherapy. Expressing chimeric antigen receptors (CARs) on T cells is a means of combining the antigen-binding site of a monoclonal ...
Carlos A, Ramos +2 more
openaire +2 more sources
Revealing Facts About CAR-T Cell Therapy [PDF]
ImmunoAnalysis, 2022 Chimeric antigen receptor (CAR)-T cell therapy is a fast-emerging treatment for several types of cancers and has several applications beyond oncology. It is a new emerging treatment targeting for a broad range of cancers.
Daggupati Sai Padmanjali +2 more
doaj +1 more source
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma [PDF]
, 2023 Chimeric antigen receptor T (CAR T)-cell therapy has become a standard treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (
Pabst, Thomas +13 more
core +2 more sources
The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
Frontiers in Immunology, 2022 Chimeric antigen receptor-T (CAR-T) cell therapy is a revolutionary adoptive cell therapy, which could modify and redirect T cells to specific tumor cells.
Hao Zhang +5 more
doaj +1 more source